Frost Health LawAlabama Attorney • Pharmacist • Healthcare Executive

Compounding analysis

A “Yes” Vote Is Not Permission to Compound: What the Peptide Decision Actually Changed

An advisory committee recommendation can signal a future policy change without creating present authority to compound.

By Toby C. “Chad” Frost • August 21, 2026
3 min read • Peptides, FDA, and 503A compounding

An advisory committee’s vote has created understandable excitement among compounding pharmacists. It has also created a dangerous amount of overstatement.

In July, the Food and Drug Administration’s Pharmacy Compounding Advisory Committee recommended adding six peptide substances to the list used for traditional pharmacy compounding: BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax. The committee rejected Emideltide. Several votes were close, including 8-6 recommendations for BPC-157, KPV, and TB-500.1

That vote did not approve the substances. It did not add them to the 503A Bulks List. The vote itself did not give a pharmacy federal authority to prepare prescriptions from those ingredients. The current regulation lists six permitted substances, none of which are among the peptides considered in July.2

The statute controls

Section 503A permits a pharmacy to use a bulk drug substance only when the ingredient meets one of three pathways. It must comply with an applicable United States Pharmacopeia or National Formulary monograph, serve as a component of an approved drug, or appear on a list developed by the Secretary through regulation.3

The committee supplies advice during that process. The Secretary still controls the legal list. Congress directed the agency to consult the committee and then issue regulations identifying substances that may or may not qualify.4

The agency’s own meeting materials confirm that it asked the committee whether these substances should be included. The materials did not announce that the ingredients had been added to the list.5

The practical line for pharmacists

Pharmacies should treat the vote as a meaningful policy signal, not a dispensing authorization. Until federal action changes the governing list or another statutory pathway applies, the recommendation alone does not cure an ineligible ingredient.

Marketing requires the same discipline. A favorable committee recommendation does not make a compounded preparation “FDA approved.” Federal regulations warn that even a drug made from a listed substance becomes misbranded if someone represents it as approved or generally endorsed by the agency.6 Compounded drugs do not undergo the agency’s premarket review for safety, effectiveness, and quality.7

The best compliance posture is simple. Do not rely on a vendor’s interpretation, a social-media headline, or an advisory vote tally. Verify the ingredient’s present statutory eligibility, document the source and certificate of analysis, review the patient-specific prescription, and monitor formal agency action.

The committee opened a door. It did not hand anyone the key.

Read the companion GLP-1 compounding analysis, review areas of experience, or see the author’s background.

Source notes

  1. Food and Drug Administration Panel Backs Six Peptides for Compounding, Am. J. Managed Care (Aug. 21, 2026).
  2. 21 C.F.R. § 216.23(a) (2026).
  3. 21 U.S.C. § 353a(b)(1)(A)(i) (2018).
  4. 21 U.S.C. § 353a(c)(1)–(2) (2018).
  5. U.S. Food & Drug Admin., July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (updated Aug. 6, 2026).
  6. 21 C.F.R. § 216.23(d) (2026).
  7. U.S. Food & Drug Admin., Compounding and the FDA: Questions and Answers (updated Sept. 16, 2025).

This article provides general information and does not constitute legal advice. It relies solely on public sources. Reading it does not create an attorney-client relationship.